How it works
How funding could work
Concise overview of a proposed way catalytic capital could support the CHR-P programme — plus one development-objective diagram and expandable detail. Not an offer · not a prospectus · not open subscription.
Last reviewed: 23 September 2026 · Proposed · Illustrative · Not an offer
Funding overview
We are evaluating a platform-supported route for eligible investors to help finance the CHR-P research programme, including a permissioned digital record of participation at closing where that proves feasible. If a platform path cannot meet legal, operational or investor-access requirements, a conventional private placement with a legal investor register remains the fallback. These are development objectives, not live offering terms. Neither path is available on this website: production investment, payment and token issuance remain inactive. Community updates and discussion are separate from any regulated investment process.
Any ~US$10 million figure is a planning target only — not money already raised, and not a claim that catalytic capital fully funds the Phase 2B programme.
Available now On this website today
- Programme information — science, public synopsis, funding use
- Scenario explorer — educational narratives, not a calculation engine
- Updates articles and Contact — email registration is coming soon (news only)
Being developed Not live
- No eligibility decision, allocation, or liquidity is offered here
- You cannot invest, pay, mint, or connect a wallet on this site
Community interest is welcome and is not an investment. Financing questions: enquiry only.
Proposed flow diagram
Eligible investors → programme vehicle → milestone releases to NWPT as sponsor → later qualifying receipts (if any) → register holders (may be zero). A permissioned digital unit under evaluation would only mirror the register; the register wins on conflict.
- Capital raised Eligible investors · private docs · not on this website
- Programme funding Bank / custody · dual control · ops milestone releases only
- NWPT as sponsor Protocol · safety · CMC · regulatory · no medical voting by holders
- Potential qualifying receipts Defined CHR-P field only · may never occur
- Contractual share to vehicle Express grant only
- Expenses / reserves Admin · reporting · holdback
- Holder distributions To register holders · may be zero
More detail
Collapsed by default. Substance already cleared for public use — no new economics.
Preferred path vs fallback
Preferred (under evaluation): a platform-integrated close for eligible investors, with a permissioned digital record of participation at closing where that proves feasible.
Fallback: a conventional private placement with a legal investor register first — without a digital unit if the platform path cannot meet legal, operational, or investor-access requirements.
Both remain development objectives, not live offering terms. Community follow is separate from any regulated investment process.
What a permissioned digital unit would and would not do
Would (if used and approved): mirror contractual units for verified holders; support information rights and negotiated protective consents as documents require; transfer only when the register allows.
Would not: grant NWPharmaTech parent equity or an automatic parent board seat; ownership of the medicine, core IP, or patient data; votes on dose, endpoints, eligibility, safety, or regulatory submissions; a public retail mint, DEX listing, or permissionless trading venue on this site; any right created only by website copy or community membership.
Distributions to register holders may be zero. Operational milestones unlock programme spend — not an investor payday.
Register primacy and transfer rules
The legal investor register is the source of truth. If a permissioned digital unit exists and balances conflict with the register, the register wins.
Transfers only among legally eligible, KYC/AML-verified investors through a transfer-agent / allowlist process, subject to legends, lockups, and any right of first refusal the documents set. No open public order book, DEX, or permissionless secondary market is part of this proposed design.
What this site does not do today
- No Invest / Subscribe / Pay / Wallet / Mint interface
- No eligibility decision, allocation, or liquidity
- No participation percentage, unit supply, issuance price, or APY
- No medical or clinical voting by investors, tokenholders, or community
- No claim that planning capital fully funds the trial
Financing questions are enquiries only. Educational scenarios: Scenario explorer (illustrative · not a forecast).
Next steps for visitors
Learn about the science · read the public synopsis · read funding use · contact us about research, press, or a financing enquiry (enquiry only — not an invest path).
Programme Funding use Proposed token Scenario explorer Contact